Tempest Therapeutics Inc
TPST7.330USD
-0.160-2.14%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.98MValor de mercado
PerdaP/L TTM
Mais detalhes de Tempest Therapeutics Inc Empresa
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Informações da empresa
Código da empresaTPST
Nome da EmpresaTempest Therapeutics Inc
Data de listagemOct 04, 2012
CEO- -
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 04
Endereço2000 Sierra Point Parkway
CidadeBRISBANE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94005
Telefone14157988589
Sitehttps://www.tempesttx.com/
Código da empresaTPST
Data de listagemOct 04, 2012
CEO- -
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
+1.29%
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
666.00
-0.15%
Mr. Michael (Mike) Raab
Mr. Michael (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
--
--
Dr. Ronit Simantov, M.D.
Dr. Ronit Simantov, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 24 de jul
Atualizado em: qui, 24 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Versant Ventures
6.87%
BlackRock Institutional Trust Company, N.A.
1.09%
Geode Capital Management, L.L.C.
0.85%
Fidelity Management & Research Company LLC
0.85%
UBS Financial Services, Inc.
0.63%
Other
89.70%
Investidores
Investidores
Proporção
Versant Ventures
6.87%
BlackRock Institutional Trust Company, N.A.
1.09%
Geode Capital Management, L.L.C.
0.85%
Fidelity Management & Research Company LLC
0.85%
UBS Financial Services, Inc.
0.63%
Other
89.70%
Tipos de investidores
Investidores
Proporção
Venture Capital
6.87%
Investment Advisor
3.49%
Investment Advisor/Hedge Fund
1.15%
Individual Investor
0.14%
Research Firm
0.08%
Bank and Trust
0.04%
Other
88.22%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
71
462.31K
11.78%
-320.03K
2025Q1
72
466.15K
11.99%
-315.34K
2024Q4
74
6.85M
15.70%
-2.07M
2024Q3
64
6.40M
25.40%
-2.51M
2024Q2
60
6.46M
29.08%
-2.26M
2024Q1
57
6.17M
27.79%
-2.56M
2023Q4
58
6.52M
33.89%
-1.52M
2023Q3
54
8.53M
66.99%
-219.33K
2023Q2
55
8.95M
101.95%
+3.83M
2023Q1
67
8.34M
99.34%
+3.30M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Versant Ventures
269.77K
6.87%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
42.91K
1.09%
+742.00
+1.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
33.33K
0.85%
+6.08K
+22.32%
Mar 31, 2025
Fidelity Management & Research Company LLC
33.23K
0.85%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
24.90K
0.63%
+11.25K
+82.43%
Mar 31, 2025
The Vanguard Group, Inc.
22.91K
0.58%
+9.36K
+69.07%
Mar 31, 2025
Susquehanna International Group, LLP
8.81K
0.22%
-682.00
-7.18%
Mar 31, 2025
Northern Trust Investments, Inc.
7.64K
0.19%
+2.43K
+46.54%
Mar 31, 2025
Brady (Stephen R)
3.61K
0.09%
+46.00
+1.29%
Apr 09, 2025
State Street Global Advisors (US)
3.19K
0.08%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proporção0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Data
Tipo
Proporção
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
Jun 25, 2021
Merger
15<1
